1887

Abstract

Sixty-three rifampicin-resistant (Rif) isolates from Kaohsiung, Taiwan, were analysed for mutations in the core region (69 bp, codons 511–533) of the gene. Some 84.1 % (53/63) of the resistant isolates showed mutations in this region, especially in codons 531 (41.5 %), 526 (18.9 %), 516 (15.1 %) and 533 (7.5 %). Five novel alleles of a total of 16 different types of mutations were identified in Rif isolates. Ten Rif isolates (15.9 %) exhibited no mutations in the core region of . Also, they did not show mutations in another 365 bp fragment (codons 99–220) of . The agar proportion method was used to determine the relationship between the degree of rifampicin resistance and alterations in the core region of . The results revealed that the mean MIC was 92.38 μg ml for the 53 isolates with a mutation in the core region, whereas the mean MIC of the other 10 isolates without mutations was only 24.8 μg ml. This indicates that the isolates with mutations in the core region had higher levels of resistance than those without mutations in this region. IS restriction fragment length polymorphism (RFLP) was used for typing of 55 Rif isolates. Isolates contained two to 19 copies of IS, with sizes ranging from 600 to 16 000 bp. The majority (85 %) contained six to 16 copies. No strains lacking IS were found. A total of 54 of 55 RFLP types were defined at the 90 % similarity level. The observation of varied IS-associated banding patterns indicates that an outbreak of drug-resistant tuberculosis did not occur in this area.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05045-0
2003-03-01
2019-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jmm/52/3/239.html?itemId=/content/journal/jmm/10.1099/jmm.0.05045-0&mimeType=html&fmt=ahah

References

  1. Bartfai, Z., Somoskovi, A., Kodmon, C. & 7 other authors ( 2001;). Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol 39, 3736–3739.[CrossRef]
    [Google Scholar]
  2. Cave, M. D., Eisenach, K. D., McDermott, P. F., Bates, J. H. & Crawford, J. T. ( 1991;). IS6110: conservation of sequence in the Mycobacterium tuberculosis complex and its utilization in DNA fingerprinting. Mol Cell Probes 5, 73–80.[CrossRef]
    [Google Scholar]
  3. Chiang, I. H., Yu, M. C., Bai, K. J., Wu, M. P., Hsu, C. J., Lin, T. P. & Luh, K. T. ( 1998;). Drug resistance patterns of tuberculosis in Taiwan. J Formos Med Assoc 97, 581–583.
    [Google Scholar]
  4. Dunlap, N. E., Harris, R. H., Benjamin, W. H., Jr, Harden, J. W. & Hafner, D. ( 1995;). Laboratory contamination of Mycobacterium tuberculosis cultures. Am J Respir Crit Care Med 152, 1702–1704.[CrossRef]
    [Google Scholar]
  5. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. ( 1999;). Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677–686.[CrossRef]
    [Google Scholar]
  6. Edlin, B. R., Tokars, J. I., Grieco, M. H. & 9 other authors ( 1992;). An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326, 1514–1521.[CrossRef]
    [Google Scholar]
  7. Goble, M., Iseman, M. D., Madsen, L. A., Waite, D., Ackerson, L. & Horsburgh, C. R., Jr ( 1993;). Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328, 527–532.[CrossRef]
    [Google Scholar]
  8. Heep, M., Rieger, U., Beck, D. & Lehn, N. ( 2000;). Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 44, 1075–1077.[CrossRef]
    [Google Scholar]
  9. Heep, M., Brandstatter, B., Rieger, U., Lehn, N., Richter, E., Rusch-Gerdes, S. & Niemann, S. ( 2001;). Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 39, 107–110.[CrossRef]
    [Google Scholar]
  10. Hui, J., Gordon, N. & Kajioka, R. ( 1977;). Permeability barrier to rifampin in mycobacteria. Antimicrob Agents Chemother 11, 773–779.[CrossRef]
    [Google Scholar]
  11. Inderlied, C. B. & Nash, K. A. (1996). Antimycobacterial agents: in vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids. In Antibiotics in Laboratory Medicine, 4th edn, pp. 127–175. Edited by V. Lorian. Baltimore: Williams & Wilkins.
  12. Jin, D. J. & Gross, C. A. ( 1988;). Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 202, 45–58.[CrossRef]
    [Google Scholar]
  13. Kan, M. ( 2000;). Current status of tuberculosis in Taiwan. Epidemiol Bull Cent Dis Control Dep Health ROC 16, 44–47.
    [Google Scholar]
  14. Kent, P. T. & Kubica, G. P. (1985). Public Health Mycobacteriology. A Guide for the Level III Laboratory. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention.
  15. Konno, K., Oizumi, K. & Oka, S. ( 1973;). Mode of action of rifampin on mycobacteria. II. Biosynthetic studies on the inhibition of ribonucleic acid polymerase of Mycobacterium bovis BCG by rifampin and uptake of rifampin-14C by Mycobacterium phlei. Am Rev Respir Dis 107, 1006–1012.
    [Google Scholar]
  16. Lisitsyn, N. A., Sverdlov, E. D., Moiseyeva, E. P., Danilevskaya, O. N. & Nikiforov, V. G. ( 1984;). Mutation to rifampicin resistance at the beginning of the RNA polymerase beta subunit gene in Escherichia coli. Mol Gen Genet 196, 173–174.[CrossRef]
    [Google Scholar]
  17. Mani, C., Selvakumar, N., Narayanan, S. & Narayanan, P. R. ( 2001;). Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol 39, 2987–2990.[CrossRef]
    [Google Scholar]
  18. Matsiota-Bernard, P., Vrioni, G. & Marinis, E. ( 1998;). Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece. J Clin Microbiol 36, 20–23.
    [Google Scholar]
  19. Ohno, H., Koga, H., Kohno, S., Tashiro, T. & Hara, K. ( 1996;). Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 40, 1053–1056.
    [Google Scholar]
  20. Ohno, H., Koga, H., Kuroita, T. & 7 other authors ( 1997;). Rapid prediction of rifampin susceptibility of Mycobacterium tuberculosis. Am J Respir Crit Care Med 155, 2057–2063.[CrossRef]
    [Google Scholar]
  21. Pozzi, G., Meloni, M., Iona, E., Orru, G., Thoresen, O. F., Ricci, M. L., Oggioni, M. R., Fattorini, L. & Orefici, G. ( 1999;). rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin Microbiol 37, 1197–1199.
    [Google Scholar]
  22. Qian, L., Abe, C., Lin, T. P., Yu, M. C., Cho, S. N., Wang, S. & Douglas, J. T. ( 2002;). rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol 40, 1091–1094.[CrossRef]
    [Google Scholar]
  23. Ramos, M. de C., Soini, H., Roscanni, G. C., Jaques, M., Villares, M. C. & Musser, J. M. ( 1999;). Extensive cross-contamination of specimens with Mycobacterium tuberculosis in a reference laboratory. J Clin Microbiol 37, 916–919.
    [Google Scholar]
  24. Shafer, R. W., Singh, S. P., Larkin, C. & Small, P. M. ( 1995;). Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in an immunocompetent patient. Tuber Lung Dis 76, 575–577.[CrossRef]
    [Google Scholar]
  25. Small, P. M., Shafer, R. W., Hopewell, P. C., Singh, S. P., Murphy, M. J., Desmond, E., Sierra, M. F. & Schoolnik, G. K. ( 1993;). Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 328, 1137–1144.[CrossRef]
    [Google Scholar]
  26. Taniguchi, H., Aramaki, H., Nikaido, Y., Mizuguchi, Y., Nakamura, M., Koga, T. & Yoshida, S. ( 1996;). Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett 144, 103–108.[CrossRef]
    [Google Scholar]
  27. Telenti, A., Imboden, P., Marchesi, F., Lowrie, D., Cole, S., Colston, M. J., Matter, L., Schopfer, K. & Bodmer, T. ( 1993;). Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647–650.[CrossRef]
    [Google Scholar]
  28. Thierry, D., Cave, M. D., Eisenach, K. D., Crawford, J. T., Bates, J. H., Gicquel, B. & Guesdon, J. L. ( 1990;). IS6110, an IS-like element of Mycobacterium tuberculosis complex. Nucleic Acids Res 18, 188.[CrossRef]
    [Google Scholar]
  29. Valim, A. R., Rossetti, M. L., Ribeiro, M. O. & Zaha, A. ( 2000;). Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J Clin Microbiol 38, 3119–3122.
    [Google Scholar]
  30. van Embden, J. D., Cave, M. D., Crawford, J. T. & 8 other authors ( 1993;). Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31, 406–409.
    [Google Scholar]
  31. van Rie, A., Warren, R., Richardson, M., Gie, R. P., Enarson, D. A., Beyers, N. & Van Helden, P. D. ( 2000;). Classification of drug-resistant tuberculosis in an epidemic area. Lancet 356, 22–25.[CrossRef]
    [Google Scholar]
  32. van Soolingen, D., de Haas, P. E., Hermans, P. W. & van Embden, J. D. ( 1994;). DNA fingerprinting of Mycobacterium tuberculosis. Methods Enzymol 235, 196–205.
    [Google Scholar]
  33. Wang, P. D. & Lin, R. S. ( 2001;). Drug-resistant tuberculosis in Taipei, 1996–1999. Am J Infect Control 29, 41–47.[CrossRef]
    [Google Scholar]
  34. Williams, D. L., Waguespack, C., Eisenach, K. & 7 other authors ( 1994;). Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 38, 2380–2386.[CrossRef]
    [Google Scholar]
  35. Williams, D. L., Spring, L., Collins, L., Miller, L. P., Heifets, L. B., Gangadharam, P. R. & Gillis, T. P. ( 1998;). Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42, 1853–1857.
    [Google Scholar]
  36. Zaza, S., Blumberg, H. M., Beck-Sague, C. & 7 other authors ( 1995;). Nosocomial transmission of Mycobacterium tuberculosis: role of health care workers in outbreak propagation. J Infect Dis 172, 1542–1549.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05045-0
Loading
/content/journal/jmm/10.1099/jmm.0.05045-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error